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ABSTRACT
Background
Despite the proven benefits of aspirin therapy in the primary and secondary prevention of
cardiovascular disease (CVD), utilization rates of aspirin remain suboptimal in relation to
recommendations. We studied national trends of aspirin use among intermediate- to high-risk
patients in the US ambulatory care settings and compared the priority given to aspirin versus
statins for CVD risk reduction. We also examined patient and health care provider contributors
to the underuse of aspirin.
Methods and Findings
We used the 1993–2003 US National Ambulatory Medical Care Survey and National Hospital
Ambulatory Medical Care Survey to estimate aspirin use by cardiovascular risk. Physician-noted
cardiovascular diseases defined high risk. Intermediate risk was defined as having diabetes
mellitus or multiple major risk factors. The proportion of patient visits in which aspirin was
reported increased from 21.7% (95% confidence interval: 18.8%–24.6%) in 1993–1994 to 32.8%
(25.2%–40.4%) in 2003 for the high-risk category, 3.5% (2.0%–5.0%) to 11.7% (7.8%–15.7%) for
visits by patients diagnosed with diabetes, and 3.6% (2.6%–4.6%) to 16.3% (11.4%–21.2%) for
those with multiple CVD risk factors. Beginning in 1997–1998, statins were prioritized over
aspirin as prophylactic therapy for reducing CVD risk, and the gaps remained wide through
2003. In addition to elevated CVD risk, greater aspirin use was independently associated with
advanced age, male gender, cardiologist care, and care in hospital outpatient departments.
Conclusion
Improvements in use of aspirin in US ambulatory care for reducing risks of CVD were at best
modest during the period under study, particularly for secondary prevention, where the
strongest evidence and most explicit guidelines exist. Aspirin is more underused than statins
despite its more favorable cost-effectiveness. Aggressive and targeted interventions are
needed to enhance provider and patient adherence to consensus guidelines for CVD risk
reduction.
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Cardiovascular disease (CVD), including myocardial in-
farction and stroke, is the leading cause of morbidity and
mortality in the United States. A broad array of randomized
trials have demonstrated the beneﬁts of low doses of aspirin
(75–325 mg) [1,2] for both the primary [3–7] and secondary
prevention [8–11] of CVD. Most trials demonstrate a 15%–
40% reduction in cardiovascular events with chronic aspirin
use. Aspirin is unequivocally recommended as a secondary
prevention strategy in non-contraindicated patients with
known CVD [12,13]. As for primary prevention, the American
Diabetic Association recommends regular aspirin for men
and women with diabetes mellitus (DM) who are older than 40
y or have additional cardiovascular risk factors [14]. In
addition, aspirin is indicated for apparently healthy individ-
uals without CVD or DM but otherwise with an increased
cardiovascular risk, which is deﬁned as a 3% or greater risk in
5 y by the US Preventive Services Task Force [2] or a 10% or
greater risk in 10 y by the American Heart Association [1].
However, the latest results from the Women’s Health Study
[7] suggest that careful ascertainment of the absolute beneﬁt
and risk on a case-by-case basis is essential to deciding on the
use of aspirin therapy in men and, even more so, in women
who have showed no clinical manifestations of CVD or
diabetes.
Despite the proven beneﬁts of aspirin therapy for
reducing cardiovascular risk, aspirin use falls considerably
short of recommendations. National surveys of the prescrib-
ing of cardiac medications found that aspirin use in visits by
patients with coronary heart disease (CHD) increased
signiﬁcantly from 5% in 1980 to 32% in 1995, but then
remained unchanged or even declined in subsequent years
[15,16]. The Third National Health and Nutrition Examina-
tion Survey (also called NHANES III) data showed that
among patients with DM, only 37% of those with CHD and
13% of those with risk factors for CHD were regular aspirin
users [17]. While aspirin underutilization is also present in
other countries [18,19], some evidence suggests that the
problem is more prominent in the US. For instance,
outpatient use of aspirin for secondary prevention ranged
from approximately 40% to 90% in many European
countries, in comparison to approximately 24% in the US
[15,20–23]. Greater aspirin use is associated with middle to
older age (55–75 y old), male gender, diagnosis of hyper-
lipidemia, smoking, having medical insurance, revasculariza-
tion or coronary angioplasty, and use of other medications
[24–28].
Despite ample evidence of aspirin underutilization, re-
search on national trends of outpatient aspirin use by CVD
risk category is limited. Using two companion national
datasets on ambulatory care in the US, our study tracked
changes from 1993–2003 in reported aspirin use by CVD risk
status, distinguishing between secondary and primary pre-
vention. Multiple reasons may account for the widespread
aspirin underutilization, one being lower priority assigned to
aspirin therapy compared to other medications available for
CVD risk reduction. To explore this possibility, we examined
the priority given to aspirin in comparison to statins. We also
examined patient and physician contributors to shortfalls in
aspirin use.
Methods
The Stanford University Institutional Review Board deter-
mined that this study was exempt from ‘‘human subjects’’
requirements.
Data Sources
We obtained annual data 1993–2003 from the National
Ambulatory Medical Care Survey (NAMCS) and the Out-
patient Department component of the National Hospital
Ambulatory Medical Care Survey (NHAMCS). The National
Center for Health Statistics provides complete descriptions
of both surveys and yearly data at http://www.cdc.gov/nchs/
about/major/ahcd/ahcd1.htm. These surveys, particularly
NAMCS, have been validated against other data sources
[29,30] and utilized in past research on aspirin use for CVD
risk reduction [16,25].
In brief, NAMCS captured health-care services provided by
private ofﬁce-based physicians, while NHAMCS captured
services offered at hospital outpatient departments. The
sampling universe for NAMCS was ofﬁce-based, patient-care
physicians in 15 specialty strata from the master ﬁles
maintained by the American Medical Association and Amer-
ican Osteopathic Association. The sampling frame for
NHAMCS included short-stay (shorter than 30 d) hospitals,
or general-specialty (medical or surgical) or children’s general
hospitals.Bothsurveysutilizedmultistageprobabilitysampling
procedures, which enable researchers to generate nationally
representative estimates. Between 1993 and 2003, annual
participation rates among physicians selected for NAMCS
averaged70%,whiletheparticipationrateofselectedhospitals
with outpatient departments was 90% in NHAMCS. Standard
encounter forms were completed for a systematic random
sample of patient visits during randomly assigned reporting
periods. Yearly encounter forms varied slightly between
NAMCS and NHAMCS and were revised every 2 y. We based
this study on variables common to NAMCS and NHAMCS over
time, including patient demographics, visit characteristics,
reasons for visit (up to three), diagnoses (up to three), and new
and continuing medications (up to ﬁve in 1993–1994, six in
1995–2002, and eight in 2003). Item nonresponse rates were
mostly 5% or less in both surveys for all years.
Patients
CHD risk categorization. We deﬁned four mutually
exclusive categories of CVD risk based on the presence of
speciﬁc diagnoses and risk factors. The presence of CHD,
myocardial infarction, stroke or transient ischemic attack,
peripheral vascular disease, claudication, or angina deﬁned
high CVD risk. In the absence of known CVD, visits by
patients with DM who were older than 40 y or had additional
risk factors (i.e., hypertension, smoking, dyslipidemia, and/or
albuminuria) were deﬁned as intermediate risk. The remain-
ing patients were deﬁned in a second intermediate risk
category if they met either of the following criteria: (1) Two
or more major CVD risk factors (i.e., hypertension, smoking,
and/or dyslipidemia) among men age 45–54 and women age
55–64; or (2) One or more risk factors among men older than
55 and women older than 65. Patient visits ineligible for any
of the former three categories were considered low risk. The
absence of data elements such as family history of premature
CHD or levels of high-density lipoprotein cholesterol
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Framingham risk scoring [31].
Patient visit characteristics. We included the following
patient visit characteristics: patient age, gender, race/ethnicity,
health care insurance status, visit status, US census region,
metropolitan area status, and physician specialty. Health care
insurance was classiﬁed as private/commercial insurance,
public insurance (i.e., Medicare and Medicaid), and other
insurance (e.g., workers’ compensation and self-pay). Visit
status distinguished ﬁrst-time visits from return visits to a
physician’s practice. Physician specialty was availableonlyfrom
NAMCS, which contributed more than 90% of the total
weighted visits for each of the study years. We categorized
physicianspecialtiesintocardiology,internalmedicine,general
and family practice, and a category encompassing all others.
Measures
Our primary analytic goals were to assess the probability of
aspirin use by CVD risk and its relationship to patient visit
characteristics. The probability of aspirin use was deﬁned as
the proportion of non-contraindicated patient visits in which
aspirin or a therapeutically equivalent medication was
reported as a new or continuing medication. Measuring the
probability of use by CVD risk provided a means to estimate
the gaps between current practice and evidence-based
medicine regarding aspirin therapy. We deﬁned aspirin
therapy as reported use of generic or brand name forms of
aspirin, clopidogrel, ticlopidine, or non-narcotic combination
analgesics containing aspirin. The number of patient visits in
which clopidogrel or ticlopidine was reported is too small to
allow their use over time being tracked separately. Oral
anticoagulants are not considered aspirin equivalents and are
not recommended for the primary or secondary prevention of
CVD in a vast majority of patients. Moreover, judging the
appropriateness of using or avoiding aspirin for someone who
is already on anticoagulant therapy required more clinical
detail than our data sources can provide. Therefore, we felt it
was appropriate to exclude patients on anticoagulant therapy.
We were unable to assess patients’ use of over-the-counter
aspirin if it was not reported on the encounter form. We
excluded visits by patients younger than 21 y and those with
bleeding tendency, gastrointestinal bleeding, anticoagulant
therapy, or clinically active hepatic disease.
Statistical Analyses
Statistical analyses accounting for sampling weights and the
complex sample designs of NAMCS and NHAMCS were
performed using SAS for Windows software (SAS Institute,
Cary, North Carolina, UnitedS t a t e s )a n dS A S - c a l l a b l e
SUDAAN software (RTI, Research Triangle Park, North
Carolina, United States). The unit of analysis in both surveys
was the patient visit. Comparisons of NAMCS and NHAMCS
suggested limited differences on key outcome measures. We
therefore combined the two surveys to obtain a wider range
of outpatient settings and a broader socioeconomic spectrum
of patients seeking ambulatory care. Also, to minimize
random ﬂuctuations between years, we analyzed data in 2-y
groupings, except for 2003, for depicting temporal trends in
aspirin use. The SAS SURVEYMEANS procedure was
performed, which generated national estimates of the
probability of aspirin use by CVD risk and corresponding
99% conﬁdence intervals (CIs). We chose to report 99% CIs
in following National Center for Health Statistics analytical
guidelines and also as a conservative measure to avoid over-
interpretation of the ﬁndings. Chi-square tests were per-
formed using PROC CROSSTAB in SUDAAN to examine the
association of aspirin use with each patient visit characteristic
based on combined 1993–2003 NAMCS and NHAMCS data.
The independent effect of each patient visit characteristic on
aspirin use after controlling for all other characteristics was
assessed with a multivariate logistic regression model using
PROC RLOGISTIC in SUDAAN. The model produced
adjusted odds ratios and 99% CIs.
Results
The volume of outpatient visits by patients identiﬁed as
being at elevated risk for future CVD events, particularly
those at intermediate risk, rose markedly over the study
period. The number of high-risk patient visits increased by
33% from 44.2 (99% CI, 41.0–47.4) million in 1993–1994 to
58.8 (54.0–63.6) million in 2001–2002. The number of
intermediate-risk patient visits in which a diagnosis of DM
was noted more than doubled, from 40.5 (37.1–43.9) million
to 83.3 (77.4–89.3) million, and for those with multiple risk
factors the increase was 57%, from 70.2 (65.7–74.7) million to
110.4 (102.8–118.0) million. The number of low-risk patient
visits rose by 23%, from 975.4 (962.6–988.2) million to 1.20
(1.18–1.22) billion. In 2003, the number of patient visits in
each of the four risk categories was 29.5 (22.5–36.6) million
for high-risk patients, 39.9 (32.0–47.9) million for intermedi-
ate-risk patients, 55.8 (45.5–66.2) million for those with
multiple risk factors, and 626.9 (537.1–716.7) million for
those with low risk.
Trends over time showed improved, though still substan-
tially suboptimal, aspirin use in the high and intermediate
risk categories, with sustained improvements seen beginning
in 1999–2000 (Figure 1). The probability of aspirin use among
patient visits in 1993–1994 was 21.7% (18.8%–24.6%) for the
high-risk category, 3.5% (2.0%–5.0%) for the diabetic,
intermediate-risk category, and 3.6% (2.6%–4.6%) for the
other intermediate-risk category. The probabilities for these
Figure 1. National Trends in Aspirin Use in Patient Visits Defined as Low
Risk, Intermediate Risk, DM, or High Risk
DOI: 10.1371/journal.pmed.0020353.g001
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essentially unchanged through 1999–2000. Increases were
observed in 2001–2002 and persisted in 2003. The probability
of aspirin use in 2003 was 32.8% (25.2%–40.4%) for the high-
risk category, 11.7% (7.8%–15.7%) for the diabetic, inter-
mediate-risk category, and 16.3% (11.4%–21.2%) for the
other intermediate-risk category. Aspirin use remained 1%–
3% among low-risk patient visits.
To explore the relative priority assigned to aspirin and
statins, we examined trends in the co-prescribing of the
medications. For this series of analyses, the number of visits
by patients with DM was relatively small and were therefore
grouped with those with known CVD to compose the high-
risk category. Both aspirin and statins were used more
frequently when the other therapy was present; however,
improvements over time were more evident for statin use
among aspirin-treated patient visits than for aspirin use
among statin-treated patients. Speciﬁcally, the proportion of
visits by high-risk patients on aspirin while a statin was used
declined modestly from 36.5% (24.9%–48.2%) in 1993–1994
to 25.6% (20.1%–31.1%) in 1999–2000 but then rebounded to
43.9% (35.1%–52.8%) in 2003 (Figure 2). In contrast, statin
use among visits by high-risk patients on aspirin grew
successively from 11.6% (7.4%–15.7%) to 54.3% (45.7%–
63.0%) (Figure 2). Of visits by intermediate-risk patients, the
probability of aspirin use when on a statin increased from
6.0% (1.4%–10.6%) in 1993–1994 to 33.8% (21.5%–46.0%) in
2003, while the probability of statin use when on aspirin rose
from 8.8% (2.2%–15.3%) to 48.1% (35.2%–61.0%) (Figure 3).
The association of greater aspirin use with higher CVD risk
was conﬁrmed by multivariate logistic regression (Table 1).
After adjusting for patient visit characteristics and the
number of medications reported, aspirin use was over four
time as likely among visits by high-risk patients and
approximately two times as likely among visits by patients
with multiple risk factors as it was among low-risk patient
visits. The odds ratio was marginally signiﬁcant for the
diabetic, intermediate-risk category. The signiﬁcance of
increases in aspirin use over time did not sustain in the
multivariate logistic regression. As for patient visit character-
istics, lower probability of aspirin use was found among 20- to
44-y-olds (versus those 45 y or older), women (versus men),
visits to noncardiologists (versus visits to cardiologists),
return visits (versus ﬁrst-time visits), and visits to private
physician ofﬁces (versus visits to hospital outpatient depart-
ments). Finally, the probability of aspirin use was positively
associated with the number of medications reported (odds
ratio, 1.71; 99% CI, 1.65–1.76).
Discussion
This study documents national trends in the probability of
aspirin use by CVD risk category among patient visits to
ofﬁce-based physicians and hospital outpatient departments.
Some improvements were observed over time in the use of
aspirin for both the secondary and primary prevention of
CVD. However, the magnitude of those improvements is
minimal relative to the substantial gaps between clinical
practice and evidence-based recommendations. The gaps
observed with secondary prevention are particularly con-
cerning, given the existence of conclusive clinical evidence
and unequivocal practice guidelines. The use of aspirin
among primary prevention patients, including those with
diabetes, also appears to be suboptimal, but additionally may
reﬂect uncertainty about the evidence. Our analysis also
suggests that despite aspirin’s more favorable cost-effective-
ness, statins have been prioritized ahead of aspirin as therapy
for reducing CVD risk.
While ample evidence attests to the underuse of aspirin in
reducing risks of CVD, this study uniquely provides an 11-y
trajectory of aspirin use in US outpatient settings and reveals
that improvements have been at best modest. The magnitude
of improvements seems particularly small in the context of
often-repeated national guidelines and abundant clinical
evidence supporting aspirin use for the prevention of CVD,
particularly in patients with known CVD. Even in 2003,
aspirin use was reported in only one-third of the visits by
patients having CVD, which points to widespread under-
appreciation of aspirin as an efﬁcacious and cost-effective
secondary prevention therapy. The usage was 12% among
Figure 2. National Trends in Aspirin and Statin Use When the Other
Therapy Is Present among High-Risk Patient Visits
Vertical bars indicate 99% CIs.
DOI: 10.1371/journal.pmed.0020353.g002
Figure 3. National Trends in Aspirin and Statin Use When the Other
Therapy Is Present among Intermediate-Risk Patient Visits
Vertical bars indicate 99% CIs.
DOI: 10.1371/journal.pmed.0020353.g003
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This was lower than the 16% found among visits by patients
with multiple major cardiovascular risk factors for whom
evidence supporting prophylactic aspirin therapy is less
deﬁnitive. The continued increases in aspirin use since
1999–2000 may reﬂect heightened awareness of the beneﬁts
of aspirin in reducing cardiovascular morbidity and mortal-
ity, mediated through intensiﬁed dissemination of national
guidelines and clinical trial ﬁndings [2,9–11,32]. We did not
ﬁnd evidence of aspirin overuse in low-risk patients.
Compared with clinical practice in Europe [22,23], our
study results add support to the observation that underuse of
aspirin is more problematic in the US. The genesis of this gap
is likely multifactorial and open to postulation. For instance,
US physicians may face greater pressure than their European
colleagues to prescribe newer medications as a result of less-
restrictive regulations on drug advertising. Also, direct-to-
consumer advertising has been shown to change patient-
physician relationships and physician prescribing behavior.
The widespread aspirin underutilization could be partly
due to uncertainties in risk assessment. Health care providers
show little consistency as to how much risk of excess bleeding
is acceptable, which may partly account for the variability in
aspirin prescribing [33]. Data indicate that aspirin use is
linked to approximately 2.5%–4.5% of the annual upper
gastrointestinal events (symptomatic ulcers) and 1%–1.5% of
serious complications, such as severe bleeding, perforation,
and obstruction [34]. These risk estimates should be evaluated
in the context of average reductions of 1540% in cardio-
vascular events when aspirin is used as a preventive therapy
[3,10,11,14,35]. Accurate risk assessment can be difﬁcult at the
individual patient level, especially when discrepancies arise
between verbal and written medical history information [36].
Aspirin resistance may also limit the rates of aspirin use.
However, the frequency of aspirin resistance is less well
known and may range from 5% to 60% [37]. In some patients
it may be dose related. Lee et al. [38] indicate that even a low-
dose aspirin of 100 mg or less may increase aspirin resistance
in patients with coronary artery disease.
Past research also suggests that physicians may assign lower
priority to aspirin therapy than to other cardiovascular risk-
lowering therapies [25,26,36], and our evaluations of the co-
prescription of aspirin and statins support this assessment.
We found that aspirin and statin use was signiﬁcantly higher
when the other therapy was present; however, the incremen-
tal use became progressively greater for statins over time.
Beginning in 1997–1998, statin use in the presence of aspirin
transcended aspirin use in the presence of statins for both the
high- and intermediate-risk categories, and the gaps re-
mained wide through 2003. These results suggest that even
though statins themselves may be underused, aspirin is given
even lower priority for lowering cardiovascular risk. These
Table 1. Predictors of Aspirin Use With Combined 1995–2002 NAMCS and NHAMCS Data
Category Significant Factors Adjusted Odds Ratios
a Wald v
2
CHD risk Low
Multiple Risk Factors
Diabetes
High
Reference
1.65 (1.36, 2.00)
1.18 (0.94, 1.49)
4.41 (3.60, 5.40)
381.5
Age group 20–44 y
45–64 y
65–79 y
. 80 y
Reference
1.97 (1.61, 2.41)
2.53 (2.07, 3.09)
2.86 (2.25, 3.65)
158.4
Sex Male
Female
Reference
0.57 (0.51, 0.63)
200.7
Medical insurance Private
Medicare/Medicaid
Other
Reference
1.01 (0.88, 1.16)
0.86 (0.71, 1.05)
5.4
Health care provider specialty Cardiology
IM
GP/FP
Other
Reference
0.37 (0.29, 0.48)
0.31 (0.25, 0.38)
0.22 (0.17, 0.27)
319.6
Race/ethnicity Non-Hispanic white
Non-Hispanic African American
Hispanic
Other
Reference
0.85 (0.69, 1.05)
0.81 (0.60, 1.09)
0.86 (0.61, 1.21)
8.1
Region West
Northeast
Midwest
South
Reference
1.11 (0.90, 1.37)
1.19 (0.96, 1.48)
1.02 (0.83, 1.27)
6.1
Residence area Non Metropolitan Area
Metropolitan Area
Reference
0.95 (0.80, 1.14)
0.5
First-time patient visit No
Yes
Reference
1.31 (1.12, 1.53)
20.5
Survey type NHAMCS
NAMCS
Reference
0.61 (0.50, 0.74)
44.8
Year 1.00 (0.98, 1.03) 0.3
Number of medications 1.71 (1.65, 1.76) 1928.0
aThe odds ratio for each variable was adjusted for all other variables listed in the table. Numbers in parentheses are 99% CIs.
DOI: 10.1371/journal.pmed.0020353.t001
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cardiovascular risk by similar magnitudes but differ vastly
in cost; statins are prioritized despite the far greater cost-
effectiveness of aspirin [39–41]. Also, secondary analyses of
clinical trial data indicate that aspirin and statins used in
combination may be more effective at reducing the relative
risk of CVD events than when used alone [42].
Statins are newer and more intensely advertised than
aspirin, which may partly explain the preferential use of these
drugs. Lipid-lowering medications already ranked the ﬁfth
most promoted drug class in the US in 1998 [43]. Statins are
proven effective for both the primary and secondary
prevention of CVD, whereas the effectiveness of aspirin in
primary prevention is less certain. Also, while they are
increasingly used as a prophylactic treatment, statins are still
most commonly prescribed to people with hyperlipidemia. In
contrast, use of aspirin is not speciﬁc to any risk factor in the
prevention of CVD and therefore may be neglected by many
physicians who are trained to perform in an overly acute-
care-centered health care system. In addition, statins may be
perceived to have a more favorable side-effect proﬁle than
aspirin, which has been shown to increase the risk of severe
gastrointestinal and cerebral hemorrhage [34]. Finally, our
comparison of aspirin and statin use is confounded by the
likelihood of underreporting of over-the-counter aspirin use
by participating physicians and clinical staff.
In agreement with previous ﬁndings, lower aspirin use is
associated with female gender, younger age, noncardiologist
care, and care in the private ofﬁce setting [15,16,27,28,44,45].
The appropriateness of prophylactic aspirin therapy among
women, particularly those under 65 y of age, is yet to be
determined in light of the new evidence from the Women’s
Health Study [7]. However, variations of aspirin use by
physician specialty and type of health care setting raise
questions about equity in the process of care. As a result of
high penetration of managed care, patients are increasingly
less likely to see a specialist such as cardiologist, unless
referred by their primary care provider [45]. Primary care
providers, including those who practice in private ofﬁces, are
expected to adhere more diligently to practice guidelines in
this area that was previously the domain of specialists.
Our ﬁndings should be interpreted in the context of
several limitations of the data sources used. Both NAMCS and
NHAMCS are designed to produce national estimates on the
basis of patient visits, and they provided no way to link
multiple visits by the same patient. The per-patient visit
nature of our analysis may lead to overestimation of aspirin
use, particularly for high-risk patients, due to more frequent
visits by sicker patients and indiscriminate reporting of
sporadic and long-term use of aspirin. Individuals who have
visited an ambulatory care facility may differ from those who
fail to do so or do so less frequently. However, observed
aspirin use may underestimate actual administration due to
its low-cost, over-the-counter availability, although partic-
ipating physicians and clinical staff are instructed to record
nonprescription medication. In an attempt to indirectly
gauge the potential of underreporting of aspirin use, Stafford
[16] studied the reporting of multivitamin use during
pregnancy and nonprescription analgesic use for osteo-
arthritis, and concluded that these surveys capture a
reasonably substantial proportion of nonprescription medi-
cation use. By limiting the number of medications reported
to six or fewer, some medications, particularly those
perceived as less critical for the treatment of primary
diagnoses, may not be reported. When we compared patient
visits in which the maximum number of medications were
reported with visits in which fewer were reported, we found
no differences in the likelihood of aspirin use. If aspirin is, in
fact, under-reported, less clinical attention and priority may
be given to aspirin use compared to other therapies.
While these data limitations present certain difﬁculties in
interpreting the absolute usage of aspirin, they should have
limited impact on our trend analysis. The extent of under-
reporting may have attenuated over time due to increased
awareness of its effectiveness in cardiovascular risk reduction,
which could partly explain the increasing trends in use that we
observed. We have no reason to believe that under-reporting
varies so substantially by patient visit characteristics that it
could have confounded our multivariate logistic analysis.
In conclusion, improvements in aspirin use for reducing
risks of CVD among US outpatients are at best modest, and
substantial treatment gaps persist, particularly in secondary
prevention, for which deﬁnitive evidence of beneﬁts is
available. Aspirin is more underused than statins despite its
more favorable cost-effectiveness. Marked changes in clinical
practice are unlikely to occur unless more aggressive,
innovative means are implemented to enhance health care
provider and patient adherence to consensus guidelines on
aspirin therapy to prevent CVD events. In particular, targeted
interventions may be warranted in patient subpopulations in
which aspirin use is lower than average, including women,
young adults, and ethnic minorities. Targeted continuing
medical education for primary care providers especially in
solo or small-group practices, may introduce greater con-
sistency into practice by specialty and practice setting.
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Patient Summary
Background Aspirin is known to be effective in lessening the chance of
heart attack, stroke, or other cardiovascular diseases that may occur
when blood vessels are blocked by blood clots. Therefore, guidelines
recommend that certain groups of people take aspirin regularly either to
prevent such clots forming in the first place, or after such a clot has
formed to prevent further clots. However, aspirin may increase the
chance of bleeding in some people; hence it is important that the
benefits of taking aspirin are balanced against possible side effects.
Why Was This Study Done? The researchers wanted to investigate
temporal patterns of aspirin use among patients who would potentially
benefit from taking it, and ask whether there were any particular
reasons—for either patients or their health care providers—that
influenced such use.
What Did the Researchers Do and Find? They used data over 11 years
from two nationwide surveys in the US that study prescribing patterns in
outpatients. Some improvements were observed between 1993 and
2003 in the use of aspirin among patients with known CVD and those
without. However, the magnitude of those improvements is minimal
relative to the substantial gaps between clinical practice and evidence-
based recommendations. From 1997 to 1998 onward, statins were used
more frequently compared with aspirin as prophylactic therapy for
reducing cardiovascular disease risk. Greater aspirin use was seen most
frequently in people of advanced age, who were male, who were being
cared for by cardiologists (rather than general physicians or other
specialists), and who were being seen in hospital outpatient depart-
ments (rather than private practices).
What Do These Findings Mean? Although there is very good evidence
that aspirin is particularly useful when given after a cardiovascular
event—so-called secondary prevention—there were only modest
increases in the use of aspirin in this period. Aspirin is less frequently
used than statins, despite its greater cost-effectiveness. Innovative
interventions are needed to enhance patients’ and health care providers’
understanding of and adherence to the guidelines that have been
developed on reducing the risk of cardiovascular disease.
Where Can I Get More Information Online? MedlinePlus has
information on aspirin and related drugs:
http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202515.html
Omni is a UK-based free catalog of hand-selected and evaluated Internet
resources in health and medicine, including a page of links on aspirin:
http://omni.ac.uk/browse/mesh/D001241.html
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